Índice neutrófilo linfocitario, corazón y COVID-19

Suilbert Rodríguez Blanco, Lázara Mirta Pérez Yanez, José M. Aguilar Medina

Texto completo:

PDF

Resumen

La infección por el nuevo coronavirus SARS-CoV2, que provoca la enfermedad COVID-19, genera  daño miocardio en un subgrupo importante de pacientes. Esto se ha relacionado con la presencia de  inflamación sistémica y miocárdica donde intervienen varios  marcadores inflamatorios, uno de ellos, es el índice neutrófilo linfocitario. El objetivo de este artículo es describir la relación del índice neutrófilo linfocitario, como biomarcador cardiaco, con el daño miocárdico que puede aparecer durante la infección por la enfermedad.  Se realizó una revisión no sistemática de la evidencia publicada  en diferentes bases y se seleccionaron 37 bibliografías de la temática.

Palabras clave

nuevo coronavirus SARS-CoV2, corazón, índice neutrófilo linfocitario.

Referencias

Bibliografía:

-Hendren NS, Drazner MH, Bozkurt B, Cooper, Jr. LT. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020;141:1903–14. https://doi.org/10.1161/circulationaha.120.047349

-Li T, Lu H and Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687-90.

-Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8.

-Singh S, Sharma A, Arora SK. High producer haplotype (CAG) of -863C/A, -308G/A and -238G/A polymorphisms in the promoter region of TNF-alpha gene associate with enhanced apoptosis of lymphocytes in HIV-1 subtype C infected individuals from North India. PLoS One. 2014;9(5):e98020

-Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395: 497-06. doi: 10.1016/S0140-6736(20)30183-5

-Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395: 507-13. DOI:https://doi.org/10.1016/S01406736(20)30211-7

-Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-69.doi:10.1001/jama.2020.1585

- Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; doi:10.1001/jamainternmed.2020.0994

- Qin C , Zhou L , Hu Z, Zhang S, Yang S, TaoY et al . Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2020. https://doi.org/10.1093/cid/ciaa248

-Deng Y, Liu W, Liu K, Yuan-Yuan F, Jin S, Ling Z et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J. 2020;133:1261-67.

- Shi S, Qin M, Shen B, Cai Y, Liu T, Fan Yang, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020.doi:10.1001/jamacardio.2020.0950.

-Guo T, Fan Y, Chen M, Chen M, Wu X, Zhang L et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020:e201017.doi:10.1001/jamacardio.2020.1017.

- Faria SS , Fernandes PJ , Silva MJ, Lima VC, Fontes, Freitas-Junior R et al. The neutrophil-to-lymphocyte ratio: a narrative review. Ecancermedicalscience. 2016;10:702 . doi:10.3332/ecancer.2016.702

- Ridker PM, Everett BM, Thuren T, J.G. MacFadyen, W.H. Chang, C. Ballantyne et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.doi: 10.1056/NJJMoa1707914.

-Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E et al. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2016;67:2050–60. https://doi.org/10.1016/j.jacc.2016.01.073

-Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol. 2006;47:962-8.

-Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S et al. Lipoprotein-associated phospholipase A (2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536–44. DOI:https://doi.org/10.1016/S0140-6736(10)60319-4

-Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes Jr D, O’Neill WW et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007;297:43–51. doi:10.1001/jama.297.1.43

- Uzma Gul, Sajjad Hussain, Rubab Munir and Azhar Mehmood Kayani. Neutrophil Lymphocyte Ratio: A prognostic marker in acute ST elevation myocardial infarction. Journal of the college of physicians and surgeons Pakistan. 2017;27(1):4-7

- Ema Tahto, Radivoj Jadric, Lamija Pojskic and Esmeralda Kicic. Neutrophil-to-lymphocyte ratio and Its relation with markers of inflammation and Myocardial necrosis in patients with acute coronary syndrome. Med arch. 2017;71(5):31215. doi: 10.5455/medarh.2017.71.312-315

- Avci BS, Avci A, Dönmez Y, Kaya A, Gülen M, Özer AL et al. The effectiveness of neutrophil-lymphocyte ratio in predicting in-hospital mortality in non-ST-elevation myocardial infarction. Emergency medicine international. 2020; Article ID 8718304. https://doi.org/10.1155/2020/8718304

- Adam J. Nelson, Stephen Nicholls, A. Lincoff, Venu Menon, Jeffrey Riesmeyer, Giacomo Ruotolo et al. Elevated levels of the neutrophil to lymphocyte ratio predicts incidence of major adverse cardiovascular events in high risk patients: insights from accelerate. JACC. 2018;71(11):e33 DOI:10.1016/S0735-1097(18)30574-6

- Cappannoli L, Scacciavillani R, Iannaccone G, Anastasia G, Di Giusto F, Loria V et al. 2019 Novel-coronavirus: Cardiovascular Insights about Risk Factors, Myocardial Injury, Therapy and Clinical Implications. Chronic Dis Transl Med. 2020. doi: 10.1016/j.cdtm.2020.06.002

-Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin res cardiol. 2020;109(5):531-38. doi: 10.1046/j.1440-1843.2003.00522.

- Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020. doi: https://doi.org/10.1016/j.jacc.2020.03.031.

- Giulio G. Stefanini, Matteo Montorfano, Daniela Trabattoni, Daniele Andreini, Giuseppe Ferrante, Marco Ancona et al. ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes. Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.047525.

- Zhe Zhua, Ting Caib, Lingyan Fanb, Kehong Loub, Xin Huab, Zuoan Huangb et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. International Journal of Infectious Diseases 2020;95:332–39.

- Liu J, Li S, Liu J, Liang B, Wang X, Wang H et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARSCoV-2 infected patients. MedRxiv 2020.

doi: https://doi.org/10.1101/2020.02.16.20023671

- Wang D, Hu B, Hu Ch, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-69. doi:10.1001/jama.2020.1585.

- Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li Ch et al. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. medRxiv 2020. DOI: https://doi.org/10.1101/2020.02.10.20021584

-Bicheng Zhang, Xiaoyang Zhou, Chengliang Zhu, Fan Feng, Yanru Qiu, Jia Feng et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. MedRxiv. 2020. https://doi.org/10.1101/2020.03.12.20035048.

-Francisco Alejandro Lagunas‐Rangel. Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID‐19): A meta‐analysis. J Med Virol. 2020. https://doi.org/10.1002/jmv.25819.

- Liu Y, Du X, Chen J, Jin Y, Peng L, Wang H.H.X et al.Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. Journal of Infection. 2020;17:28 https://doi.org/10.1016/j.jinf.2020.04.002

- Suilbert Rodríguez Blanco, Abel Y. Leyva Quert, José M. Aguilar Medina, Pedro M. Collazo, Enmanuel Hernández Váldes, Juan Carlos Perez et al. Valor del índice neutrófilo-linfocitario en la predicción de la severidad de enfermedad arterial coronaria. Revista Cubana de Cardiología y Cirugía Cardiovascular. 2020;26(1):1-6

- Suilbert Rodríguez Blanco, Abel Y Leyva Quert y José M Aguilar Medina. Índice neutrófilo-linfocitario en la predicción de trombosis temprana del stent. Revista Argentina de Cardioangiología Intervencionista. 2020;(01):0017-0020 Doi: 10.30567/RACI/202001/0017-0020

- Park JJ, Jang HJ, Oh IY, Yoon CH, Suh JW, Cho YS et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013;111:636–42. doi: 10.1016/j.amjcard.2012.11.012

-Xiao Z, Xu C, Wang D and Zeng H. The experience of treating patients with acute myocardial infarction under the COVID-19 epidemic. Catheter Cardiovasc Interv. 2020. https://doi.org/10.1002/ccd.28951

Enlaces refback

  • No hay ningún enlace refback.




Copyright (c) 2020 Suilbert Rodríguez Blanco, Lázara Mirta Pérez Yanez, José M. Aguilar Medina

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.